Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease

In recent years, many new treatments for relapsed/refractory (R/R) multiple myeloma (MM) have improved patient prognosis, but the prognosis of patients with extramedullary MM is still particularly poor. Therefore, more efficacious therapies and novel strategies are urgently needed for these patients...

Full description

Bibliographic Details
Main Authors: Haobin Deng, Meijing Liu, Ting Yuan, Huan Zhang, Rui Cui, Jingyi Li, Jijun Yuan, Xiaofang Wang, Yafei Wang, Qi Deng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Immunology
Subjects:
anti-B cell maturation antigen chimeric antigen receptor T
multiple myeloma
relapsed
refractory
extramedullary disease
efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.720571/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.720571/full

Similar Items